Literature DB >> 28346414

Nivolumab before and after allogeneic hematopoietic cell transplantation.

F Covut1, R Pinto1, B W Cooper1,2, B Tomlinson1,2, L Metheny1,2, E Malek1,2, H M Lazarus1,2, M de Lima1,2, P F Caimi1,2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28346414     DOI： 10.1038/bmt.2017.44

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  12 in total

1.  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Authors:  Norbert Schmitz; Beate Pfistner; Michael Sextro; Markus Sieber; Angelo M Carella; Matthias Haenel; Friederike Boissevain; Reinhart Zschaber; Peter Müller; Hartmut Kirchner; Andreas Lohri; Susanne Decker; Bettina Koch; Dirk Hasenclever; Anthony H Goldstone; Volker Diehl
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

2.  Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

Authors:  Philippe Armand; Margaret A Shipp; Vincent Ribrag; Jean-Marie Michot; Pier Luigi Zinzani; John Kuruvilla; Ellen S Snyder; Alejandro D Ricart; Arun Balakumaran; Shelonitda Rose; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

3.  Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment.

Authors:  Manuel Afable; Paolo F Caimi; Chitra Hosing; Marcos de Lima; Issa Khouri; Basem M William; Yago Nieto; Brenda W Cooper; Paolo Anderlini; Stanton L Gerson; Hillard M Lazarus; Richard Champlin; Uday Popat
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-30       Impact factor: 5.742

4.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Authors:  Anas Younes; Nancy L Bartlett; John P Leonard; Dana A Kennedy; Carmel M Lynch; Eric L Sievers; Andres Forero-Torres
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

5.  CD8(+) T-cell reconstitution in recipients of umbilical cord blood transplantation and characteristics associated with leukemic relapse.

Authors:  Natacha Merindol; Martin A Champagne; Michel Duval; Hugo Soudeyns
Journal:  Blood       Date:  2011-08-02       Impact factor: 22.113

6.  Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.

Authors:  Francesco Merli; Stefano Luminari; Paolo G Gobbi; Nicola Cascavilla; Caterina Mammi; Fiorella Ilariucci; Caterina Stelitano; Maurizio Musso; Luca Baldini; Sara Galimberti; Francesco Angrilli; Giuseppe Polimeno; Potito Rosario Scalzulli; Angela Ferrari; Luigi Marcheselli; Massimo Federico
Journal:  J Clin Oncol       Date:  2015-12-28       Impact factor: 44.544

7.  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Craig H Moskowitz; Auayporn Nademanee; Tamas Masszi; Edward Agura; Jerzy Holowiecki; Muneer H Abidi; Andy I Chen; Patrick Stiff; Alessandro M Gianni; Angelo Carella; Dzhelil Osmanov; Veronika Bachanova; John Sweetenham; Anna Sureda; Dirk Huebner; Eric L Sievers; Andy Chi; Emily K Larsen; Naomi N Hunder; Jan Walewski
Journal:  Lancet       Date:  2015-03-19       Impact factor: 79.321

8.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

9.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.

Authors:  G P Canellos; J R Anderson; K J Propert; N Nissen; M R Cooper; E S Henderson; M R Green; A Gottlieb; B A Peterson
Journal:  N Engl J Med       Date:  1992-11-19       Impact factor: 91.245

10.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316
View more
  6 in total

Review 1.  Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.

Authors:  Awais Ijaz; Ali Younas Khan; Saad Ullah Malik; Warda Faridi; Muhammad Asad Fraz; Muhammad Usman; Muhammad Junaid Tariq; Seren Durer; Ceren Durer; Atlantis Russ; Nadia Nunes Cavalcante Parr; Zeeshan Baig; Fnu Sagar; Zeeshan Ali; Ali McBride; Faiz Anwer
Journal:  Biol Blood Marrow Transplant       Date:  2018-09-06       Impact factor: 5.742

Review 2.  The Role of Immune Checkpoints after Cellular Therapy.

Authors:  Friederike Schmitz; Dominik Wolf; Tobias A W Holderried
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

3.  Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients.

Authors:  Sandhya Manohar; Charat Thongprayoon; Wisit Cheungpasitporn; Svetomir N Markovic; Sandra M Herrmann
Journal:  Kidney Int Rep       Date:  2019-12-07

4.  Successful Use of Nivolumab in a Patient with Head and Neck Cancer After Allogeneic Bone Marrow Transplantation.

Authors:  Xiaopei Dong; Ning Lu; Zhongsheng Tong; Yehui Shi
Journal:  Onco Targets Ther       Date:  2021-02-10       Impact factor: 4.147

5.  Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.

Authors:  Sun Yao; Chen Jianlin; Qiao Zhuoqing; Li Yuhang; Hu Jiangwei; Hu Guoliang; Ning Hongmei; Zhang Bin; Hu Liangding
Journal:  Front Immunol       Date:  2021-04-01       Impact factor: 7.561

Review 6.  Post-hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors.

Authors:  Elham Roshandel; Farzaneh Tavakoli; Sayeh Parkhideh; Sedigheh Sadat Akhlaghi; Maria Tavakoli Ardakani; Masoud Soleimani
Journal:  Health Sci Rep       Date:  2022-03-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.